Monday, February 08, 2010 1:07:40 PM
I agree. Paul did mention that the application was filed before October but that the amendment had yet to be filed.
I look at many positive signs. Look at the talent and connections of the development team. Going through the patent application I see many references to clinical practices undertaken by Korean company. It may not be approved tomorrow but there are a lot of positives here.
The team behind the Bioharp:
-Professor of KAIST (Korean Advanced Institute of Science and Technology ) since 2004
-Technology Policy Advisor of ADD (Agency for Defense Development) 2004
-Visiting professor of Dongguk University since 2003
-Head, electronic & communication division in ADD (Agency for Defense Development)
-Chairman, Genohco.,Inc
-CEO, Genohco.,Inc
http://www.gobizkorea.com/blog/index.do?blogid=genohco
-CEO, Samwoo Telecommunication Industry in Korea from 1995 to 2004
-Managing Director, Satellite Communication Department of KT Corporation in Korea from 1991 to 2006
-Senior engineer, electronic & communication division in ADD (Agency for defense evelopment)
Pre-clinical testing:
-under the pre-clinical test regulations of the Pre-Clinical Research Center (KGLP Approval) of Chemon Inc
-0171]The kind of cancer cells were a human cancer cell line such as lung cancer (A549), colon cancer (HCT15), melanoma (LOX-IMVI), prostate carcinoma (PC-3), and breast cancer (MDA-MB-231), which were all obtained from the Korea Research Institute of Bioscience & Biotechnology in the form of freezing vials, and kept in a liquid nitrogen tank in a cell culture room of Pharmacology and Medicine Laboratory in the Pre-Clinical Researching center (KGLP Approval) of Chemon Inc
-The inventor of the present invention measured carcinogenesis in the animals by group from the first day of the cancer cell transplantation under the pre-clinical test regulations of the Pre-Clinical Research Center (KGLP Approval) of Chemon Inc. by using the early cancer diagnostic device manufactured with the functions of the biosensor
-[0159]Mice to be tested were specific pathogen free BALB/C nude mice (Athymic BALB/C Nude Mouse), which were 8 weeks old female mice removed of thymus (available from Central Lab. Animals Inc., Korea
I look at many positive signs. Look at the talent and connections of the development team. Going through the patent application I see many references to clinical practices undertaken by Korean company. It may not be approved tomorrow but there are a lot of positives here.
The team behind the Bioharp:
-Professor of KAIST (Korean Advanced Institute of Science and Technology ) since 2004
-Technology Policy Advisor of ADD (Agency for Defense Development) 2004
-Visiting professor of Dongguk University since 2003
-Head, electronic & communication division in ADD (Agency for Defense Development)
-Chairman, Genohco.,Inc
-CEO, Genohco.,Inc
http://www.gobizkorea.com/blog/index.do?blogid=genohco
-CEO, Samwoo Telecommunication Industry in Korea from 1995 to 2004
-Managing Director, Satellite Communication Department of KT Corporation in Korea from 1991 to 2006
-Senior engineer, electronic & communication division in ADD (Agency for defense evelopment)
Pre-clinical testing:
-under the pre-clinical test regulations of the Pre-Clinical Research Center (KGLP Approval) of Chemon Inc
-0171]The kind of cancer cells were a human cancer cell line such as lung cancer (A549), colon cancer (HCT15), melanoma (LOX-IMVI), prostate carcinoma (PC-3), and breast cancer (MDA-MB-231), which were all obtained from the Korea Research Institute of Bioscience & Biotechnology in the form of freezing vials, and kept in a liquid nitrogen tank in a cell culture room of Pharmacology and Medicine Laboratory in the Pre-Clinical Researching center (KGLP Approval) of Chemon Inc
-The inventor of the present invention measured carcinogenesis in the animals by group from the first day of the cancer cell transplantation under the pre-clinical test regulations of the Pre-Clinical Research Center (KGLP Approval) of Chemon Inc. by using the early cancer diagnostic device manufactured with the functions of the biosensor
-[0159]Mice to be tested were specific pathogen free BALB/C nude mice (Athymic BALB/C Nude Mouse), which were 8 weeks old female mice removed of thymus (available from Central Lab. Animals Inc., Korea
Recent MCIC News
- MultiCorp International, Inc. Announces that 40 Brightwater LLC has executed an Agreement that will fund MultiCorp International, Inc. • GlobeNewswire Inc. • 10/22/2025 01:28:03 PM
